[Market Focus] SK Bioscience Surges Over 4% on Global Phase 3 Clinical Trial Application for Varicella Vaccine

SK Bioscience is showing strong performance on September 3. The company has drawn investor attention by further developing its proprietary vaccination method to enhance competitiveness in the global varicella vaccine market.

As of 2:35 p.m. on this day, SK Bioscience is trading at 49,100 won, up 2,150 won (4.58%) from the previous trading day.

On the previous day, SK Bioscience announced that it had submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety for a global Phase 3 clinical trial to add a two-dose indication for its self-developed varicella vaccine, Sky Varicella. This announcement appears to have attracted significant investor interest.

This clinical trial aims to evaluate the immunogenicity and safety of administering two doses of the vaccine to approximately 800 children aged 12 months to 12 years, both in Korea and abroad.

The company stated that the target completion date is 2027.

According to market research firm Global Market Insights, the global varicella vaccine market is expected to grow at an average annual rate of 6.5%, from approximately 3.4 billion dollars (about 4.7 trillion won) last year to about 6.3 billion dollars (about 8.8 trillion won) by 2034.

Meanwhile, on August 20, SK Bioscience held an exclusive meeting with the Bill & Melinda Gates Foundation, the world's largest non-profit foundation, during Bill Gates' visit to Korea, to discuss cooperation measures for improving global health.

This content was produced with the assistance of AI translation services.